At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy
In Brief
A Phase 3 clinical trial evaluating FACBC and Radiation therapy for Prostate Cancer. Completed, enrolled 165 participants across 1 site.
Detailed Summary
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy. Half of these patients will have radiotherapy decision-making and delivery per the usual routine, and half of these patients will have the radiotherapy decision and volumes guided by the FACBC test (anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (anti-3- \[18F\]FACBC). The major goal of the investigation is to see whether the FACBC improves the selection and the cancer control rates of post-surgery patients with a rising PSA who undergo radiotherapy.
Study Details
Timeline
Interventions
FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.